Human pharmacokinetic/pharmacodynamic profile of irbesartan: A new potent angiotensin II receptor antagonist

Journal of Hypertension, Supplement

Volumn 15, Issue 7, 1997, Pages

  Ruilope, Luis ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Angiotensin II receptor antagonists; Hypertension; Irbesartan; Pharmacodynamics; Pharmacokinetics

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; CANDESARTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; RENIN; TASOSARTAN;

ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRESSOR RESPONSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERTENSION; MALE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 0031409881     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Ellis ML, Patterson JH: A new class of antihypertensive therapy: angiotensin II receptor antagonists. Pharmacotherapy 1996, 16:849-860.
2. Csajka C, Buclin T, Brunner HR, Biollaz J: Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997, 32:1-29.
3. Oliverio Ml, Coffman TM: Angiotensin-II receptors: new targets for antihypertensive therapy. Clin Cardiol 1997, 20:3-6.
4. Smith RD, Timmermans PBMWM: Human angiotensin receptor subtypes. Curr Opin Nephrol Hypertens 1994, 3:112-122.
5. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45:206-251.
6. Hollenberg NK: ACE inhibitors, AT, receptor blockers, and the kidney. Nephrol Dial Transplant 1997, 12:381-383.
7. Levens NR, de Gasparo M, Wood JM, Bottari SP: Could the pharmacological differences observed between Ang II antagonists and inhibitors of angiotensin converting enzyme be clinically beneficial? Pharmacol Toxicol 1992, 71:241-249.
8. Erdos EG, Skidgel RA: The unusual substrate specificity and the distribution of human angiotensin I converting enzyme. Hypertension 1986, 8:1-34-1-37.
9. Foote EF, Halstenson CE: New therapeutic agents in the management of hypertension: angiotensin II -receptor antagonists and renin Inhibitors. Ann Pharmacother 1993, 27:1495-1503.
10. Clozel J-P, Fischeli W: Comparative effects of three different potent renin inhibitors in primates. Hypertension 1993, 22:9-17
11. Hollenberg NK: Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system. J Hypertens 1997, 15 (suppl 7):S7-S13.
12. Medical Economics: Avapro (irbesartan), US product information. In Physicians'Desk Reference, 52nd edn. Montvale, New Jersey: 1998, suppl (in press).
13. 2-receptor mediates inhibition of cell proliferation in coronary endothetial cells. J Clin Invest 1995, 95:651-657.
14. 2) receptor antagonizes the growth effects of the AT, receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995, 92:10663-10667.
15. 1 subtype angiotensin II receptor antagonist J Pharmacol Exp Ther 1993, 265:826-834.
16. I (Iosartan), US product information. In Physicians'Desk Reference, 50th edn. Montvale, New Jersey: 1996:1628-1630.
17. I (valsartan), US product information. In Physicians'Desk Reference, 52nd edn. Montvale, New Jersey: 1998:1841-1843.
18. Neefe DL, Klamerus KJ, Battle MM, Mayer PR: Multiple dose safety, pharmacokinetic (PK) and pharmacodyriamic study of tasosartan in patients with mild to moderate hypertension [abstract]. Am J Hypertens 1997, 10:105A.
19. Criscione L, Bradley WA, Bühlmayer P, et al.: Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist Cardiovasc Drug Rev 1995, 13:230-250.
20. Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR: Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995, 25:14-21.
21. Marino MR, Langenbacher KM, Ford NF, Uderman HD: Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of irbesartan after single and multiple doses in healthy male subjects [abstract]. Clin Pharmacol Ther 1997, 61:207.
22. Necciari J, Denolle T, Le Coz F, Donazollo Y, Pastor G, Sissmann J: Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man [abstract]. J Hypertens 1994, 12:88.
23. Vachharajani N, Shyu WC, Mantha S, Park J-S, Greene D, Barbhaiya R: Lack of food effect on the oral bioavailability of irbesartan [abstract]. J Clin Pharmacol 1997, 37:872.
24. Marino MR, Langenbacher KM, Ford NF, Beierle F, Shamblen EC, Lasseter KC: Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of irbesartan [abstract]. Clin Pharmacol Ther 1997, 61:205.
25. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986, 261:5051 -5060.
26. Marino MR, Hammert JL, Ferreira I, Ford NF, Uderman HD: Lack of effect of nifedipine on the pharmacokinetics of irbesartan in healthy male subjects [abstract]. J Clin Pharmacol 1997, 37:872.
27. Vachharajani N, Chang SY, Shyu WC, Greene D, Barbhaiya R:The effects of age and gender on the pharmacokinetics of irbesartan. Pharm Res 1995, 12:S-388.
28. Vachharajani N, Shyu WC, Greene D, Barbhaiya R: The effect of age on the pharmacokinetics of irbesartan [abstract]. J Clin Pharmacol 1997, 37:872.
29. Sica DA, Marino MR, Hammett JL, Ferreira I, Gehr TWB, Ford NF: The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther 1997, 62:610-618.
30. Marino MR, Langenbacher KM, Raymond RH, Ford NF, Dilzer S, Lasseter KC: Pharmacokinetics and pharmacodynamics of irbesartan in subjects with hepatic cirrhosis [abstract]. J Clin Pharmacol 1997, 37:871.
31. Ribstein J, Picard A, Armagnac C, Bouroudian M, Sissmann J, Mimran A: Full antagonism of presser response to exogenous angiotensin II (angiotensin II) by single-dose irbesartan in normotensive subjects [abstract]. J Hypertens 1997, 15 (suppl 4) :S117.
32. Brunner HR, Christen Y, Munafo A, Lee RJ, Waeber B, Nussberger J: Clinical experience with angiotensin II receptor antagonists. Am J Hypertens 1992, 5 (suppl):243S-246S.
33. Munafo A, Christen Y, Nussberger J, et al. : Drug concentration response relationships in normal volunteers after oral administration of Iosartan, an angiotensin II receptor antagonist Clin Pharmacol Ther 1992, 51:513-521.
34. Powell JR, Marino M, Coniglio AA: A model to predict clinical efficacy of angiotensin II blocker (angiotensin IIB) [abstract]. J Clin Pharmacol 1997, 37:871.
35. Lasseter KC, Marino MR, Langenbacher KM, Vesterqvists O, Shamblen EC, Ford NF: Pharmacodynamics of irbesartan in subjects with mild-to-moderate hypertension [abstract]. Am J Hypertens 1997, 10:D64.